 Home > Medical News > Latest Medical News > The world's first subcutaneous PD-L1 envolimab was approved for marketing in China

The world's first subcutaneous PD-L1 envolimab was approved for marketing in China

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

termite treatment product

national graduation products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 25, the National Medical Products Administration approved the subcutaneous injection of PD-L1 antibody envolimab for MSI-H/dMMR advanced colorectal cancer, gastric cancer and other solid tumors that have failed standard treatment

The product was jointly developed by Sidi Di Pharmaceutical, Corning Jereh Pharmaceuticals, and Simcere Pharmaceuticals.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The world's first subcutaneous PD-L1 envolimab is approved for marketing in China

12-05

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

The world's first subcutaneous PD-L1 envolimab was approved for marketing in China

Related Articles

The world's first subcutaneous PD-L1 envolimab is approved for marketing in China